
J&J Imbruvica gains EU approval for untreated Mantle Cell Lymphoma in transplant eligible patients
Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has approved an indication extension of IMBRUVICA (ibrutinib) in frontline mantle cell lymphoma (MCL). The approval is for ibrutinib in …